GenSight Biologics Secures Compassionate Authorization for Gene Therapy GS010/Lumevoq in France

05:47 AM EST, 12/22/2025 (MT Newswires) -- GenSight Biologics (SIGHT.PA) said Monday the French medicines agency ANSM granted compassionate use authorization, or AAC, for its gene therapy, GS010/Lumevoq, to treat retinal neurodegenerative central nervous system disorder ND4-Lhon. The biopharmaceutical company noted that the AAC program in France allows patients to receive treatments, without marketing authorization, for rare or disabling diseases.